Publication date: 17/08/2017
argenx (Euronext & Nasdaq: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced it will host a conference call and audio webcast on Thursday, August 24, 2017 at 3:00 p.m. CEST (9:00 a.m. EDT) to discuss financial results for the first half of 2017 and to provide a second quarter business update.
To participate in the conference call, please select your phone number below and use the confirmation code 3427020. The webcast may be accessed on the homepage of the argenx website at www.argenx.com or clicking here.
Please dial in 5-10 minutes prior to 3 p.m. CET/ 9 a.m. EDT using the number and conference ID below.
Confirmation Code: 3427020
United Kingdom: +44 20 3427 1903
National free phone - United Kingdom: 0800 279 5004
USA: +1646 254 3367
National free phone - USA: 1877 280 2342
France: +33 1 76 77 22 22
National free phone - France: 0805 631 579
Belgium: +32 2 620 0138
National free phone - Belgium: 0800 58032
Netherlands: +31 20 716 8295
National free phone - Netherlands: 0800 020 2577
A question and answer session will follow the presentation of the results. The archived webcast will also be available for replay shortly after the close of the call from the "Downloads" section of the argenx website.
argenx is a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer. We are focused on developing product candidates with the potential to be either first-in-class against novel targets or best-in-class against known, but complex, targets in order to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE Antibody(TM) Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies are designed to enable us to expand the therapeutic index of our product candidates.